EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Trends in Treatment of Severe Haemophilia and Impact on Inhibitor Assessment by the EUHASS Registry

Kathelijn Fischer iD, Riitta Lassila iD, Flora Peyvandi iD, Alex Gatt, Samantha C Gouw, Rob Hollingsworth, Thierry Lambert, Radoslaw Kaczmarek iD, Diana Carbonero iD, Michael Makris iD, EUHASS participants

Haemophilia · 2025

DOI: 10.1111/hae.70039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, 2025. Verfasst von Kathelijn Fischer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht, the Ne…. Hauptthemen laut MEDLINE: Hemophilia A, Blood Coagulation Factor Inhibitors. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Commission Health Programme through the Executive Agency for Health and Consumers (EAHC), European Association for Haemophilia and Allied Disorders, Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The last 15 years have seen new extended half‐life (EHL) recombinant FVIII/IX concentrates and nonreplacement therapy for haemophilia A (emicizumab) introduced in Europe. These changes affect FVIII/IX exposure in previously untreated patients (PUPs) and previously treated patients (PTPs) with severe haemophilia A and B (SHA and SHB) and may modify inhibitor development and/or detection.

Aim

To report trends in treatment for severe haemophilia and concomitant changes in inhibitor incidence.

Methods

Between 2008 and 2022, 97 centres reported inhibitor development against FVIII/IX concentrates to the European Haemophilia Safety Surveillance System (EUHASS). Inhibitors were reported quarterly, and PUPs without inhibitor development annually. Cumulative inhibitor incidences (95% confidence intervals [CI]) were calculated for PUPs and incidence rates/1000 years (CI) for PTPs.

Results

By 2022, SHA‐PUPs ( n = 1574) received emicizumab (44%), SHL‐rFVIII (21.5%), pdFVIII (17.5%) and EHL‐rFVIII (17%). SHB‐PUPs ( n = 236) received EHL‐rFIX (79%) and SHL‐rFIX (21%). SHA‐PTPs (68,772 years) received EHL‐rFVIII (31%), SHL‐rFVIII (28%), emicizumab (25%), and pdFVIII (15%). SHB PTPs (11,185 years) received EHL‐rFIX (69%), pdFIX (15%) and SHL‐rFIX (15%). Observed Inhibitor incidence in SHA‐PUPs decreased from 24% before 2016 to 6% in 2022 ( p < 0.001), and potentially in SHB‐PUPs too (from 9% to 3%; p = 0.066), but remained stable in SHA/SHB PTPs.

Conclusion

In 2022, 44% of SHA‐PUPs and 25% of SHA‐PTPs received emicizumab prophylaxis. Concomitantly, observed inhibitor incidence reduced to 6% in SHA‐PUPs. In SHB, EHL‐rFIX treatment increased to 79% in SHB‐PUPs and 69% in SHB‐PTPs. Assessing inhibitor incidence for new concentrates is likely to be hampered by novel treatments causing delayed exposure to FVIII/FIX.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia ABlood Coagulation Factor InhibitorsHumansRegistriesFactor VIIIAntibodies, Monoclonal, HumanizedEuropeFactor IXAntibodies, BispecificMaleChild

Stichwörter der Autor:innen

PTPPUPantibodiesemicizumabfactor VIIIhaemophiliainhibitorneutralising

Substanzen

Factor VIIIAntibodies, Monoclonal, HumanizedemicizumabFactor IXAntibodies, BispecificBlood Coagulation Factor Inhibitors

Autor:innen und Institutionen

  • Center for Benign Haematology, Thrombosis and Haemostasis, Van Creveldkliniek, University Medical Center Utrecht, University Utrecht, Utrecht, the Netherlands.
  • Department of Hematology, Unit of Coagulation Disorders, Helsinki University Central Hospital, Research Program Unit in Systems Oncology, University of Helsinki, Helsinki, Finland.
  • Angelo Bianchi Bonomi, Hemophilia and Thrombosis centre, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
  • Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.
  • Mater Dei Hospital, Tal-QRoqq, Msida, Malta.
  • Department of Pediatric Hematology, Emma Children's Hospital, Amsterdam UMC location University of Amsterdam, Amsterdam, the Netherlands.

ORCID-Profile: Kathelijn Fischer, Riitta Lassila, Flora Peyvandi, Radoslaw Kaczmarek, Diana Carbonero, Michael Makris

Förderung

  • European Commission Health Programme through the Executive Agency for Health and Consumers (EAHC)
  • European Association for Haemophilia and Allied Disorders
  • Bayer
  • Biomarin
  • Biotest
  • BPL
  • CSL Behring
  • Grifols

Zitieren

APA

Fischer, K., Lassila, R., Peyvandi, F., Gatt, A., Gouw, S. C., Hollingsworth, R., Lambert, T., Kaczmarek, R., Carbonero, D., Makris, M., & EUHASS participants (2025). Trends in Treatment of Severe Haemophilia and Impact on Inhibitor Assessment by the EUHASS Registry. Haemophilia. https://doi.org/10.1111/hae.70039

Vancouver

Fischer K, Lassila R, Peyvandi F, Gatt A, Gouw SC, Hollingsworth R, et al. Trends in Treatment of Severe Haemophilia and Impact on Inhibitor Assessment by the EUHASS Registry. Haemophilia. 2025. doi:10.1111/hae.70039

BibTeX
@article{Fischer2025,
  author = {Fischer, Kathelijn and Lassila, Riitta and Peyvandi, Flora and Gatt, Alex and Gouw, Samantha C and Hollingsworth, Rob and Lambert, Thierry and Kaczmarek, Radoslaw and Carbonero, Diana and Makris, Michael and EUHASS participants, EUHASS participants},
  title = {Trends in Treatment of Severe Haemophilia and Impact on Inhibitor Assessment by the EUHASS Registry},
  journal = {Haemophilia},
  year = {2025},
  doi = {10.1111/hae.70039}
}
Kostenlos starten →